The authors compared the antitumor activity and safety in previously untreated melanoma or unresectable melanoma by a combination treatment with relatlimab, a lymphocyte activating gene-3–blocking antibody, and nivolumab, a PD-1–blocking antibody. The gene discussed is PDCD1; the disease is melanoma.